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As the dust begins to settle after a year of remarkable
advances in the understanding and treatment of human
immunodeficiency virus-1 (HIV-1) infection, it is clear that
a great deal still needs to be learned about how HIV-1 inter-
acts with its human host. Two fundamental, and almost cer-
tainly related, questions remain unanswered after more
than a decade of investigation. First, how does HIV-1 main-
tain a chronic, persistent infection? Second, why is the
immune system, while apparently active in its response to
the virus, ultimately unable to control HIV-1 infection
effectively and protect the infected individual from pro-
gression to AIDS? Ironically, rather than serving to illumi-
nate these essential questions, recent research results have
made their consideration even more perplexing.
The advent of potent anti-HIV-1 drugs has provided good
reason to believe that the outcome of HIV-1 infection will
now be substantially better for those infected individuals
fortunate enough to have access to them. These anti-viral
drugs have also provided valuable tools for studying the
kinetics of HIV-1 replication and the turnover of infected
cells in vivo. In the course of such studies, important clues
have emerged about the nature of the target cells support-
ing active or chronic HIV-1 infection. Much to the surprise
of well-meaning immunologists everywhere, however, the
new data on virus and HIV-1-infected-cell turnover in vivo
challenge the dogma that cytotoxic (CD8) T lymphocytes
(CTLs) with the potential to recognize and kill HIV-1-
infected cells play an important role in containing virus
replication during the chronic phase of the infection, and
that the onset of AIDS follows upon the failure of the host
cellular immune response.
A little learning
Elucidation of HIV-1 pathogenesis has been greatly
facilitated by the development of assays to measure the
magnitude of HIV-1 replication in vivo. Sensitive tech-
niques have been developed recently that quantify levels of
HIV-1 RNA within virus particles circulating in the plasma
of infected individuals. Recent data indicate that the level
of viremia (the ‘viral load’), as measured by the amount of
HIV-1 RNA in the plasma, accurately reflects the extent of
virus replication in an infected person [1,2]. Although lym-
phoid tissues, such as lymph nodes and other compartments
of the reticuloendothelial system, are thought to be the
largest reservoirs of virus infection in vivo, virus particles
produced in these tissues are released, through as yet
unidentified routes, into the peripheral circulation, where
they can be readily sampled. Plasma HIV-1 RNA concen-
trations are thus likely to reflect the level of active virus
replication throughout the body, although we do not yet
know whether specific compartments, such as the central
nervous system, represent sites of infection that are not in
communication with the peripheral virus pool. 
The use of plasma HIV-1 RNA assays to study the natural
history of HIV-1 infection has helped illuminate, at least in
broad outline, one of the long-standing mysteries of HIV-1
disease: why do some people progress rapidly to AIDS fol-
lowing their initial infection with HIV-1, whereas others
remain healthy for prolonged periods? The rate of decline
of CD4 (helper) T cells after initial HIV-1 infection varies
considerably from person to person, and is not constant
throughout all stages of the infection. Recent data demon-
strate clearly that the magnitude of HIV-1 replication is the
primary factor driving the depletion of CD4 T cells and
disease progression [3,4].
An acceleration in the rate of decline of CD4 T-cell
numbers heralds the progression of disease, but the virolog-
ical and immunological events that occur around this time
remain obscure. During primary HIV-1 infection, when
there are numerous susceptible target cells without a coun-
tervailing host immune response, plasma HIV-1 RNA
levels can exceed 107 copies per milliliter. About the time
that detectable levels of HIV-1-specific CTLs emerge, the
levels of plasma HIV-1 RNA decline precipitously (by two
to three orders of magnitude or more). It is not, however,
known whether this association is causal or coincidental
(see below). After a period of fluctuation, often lasting six
months or so, plasma HIV-1 RNA levels appear to stabilize
around a so-called ‘set point’.
Different infected individuals display different steady-state
levels of viral replication. Those individuals with higher
steady-state ‘set-point’ levels of plasma HIV-1 RNA lose
CD4 T cells more quickly, progress to AIDS more rapidly
and die sooner than those with lower HIV-1 RNA set-point
levels [3,4]. The determinants of this set point are incom-
pletely understood, but probably include the number of
target cells available for infection (a function of the absolute
levels of susceptible T cells and macrophages, their state of
activation and the expression of specific co-receptor mol-
ecules governing virus entry into target cells), the degree of
immune activation, and the tropism (specific target cell
preference) and replicative vigor (or ‘fitness’) of the prevail-
ing HIV-1 strain at various times following the initial infec-
tion, as well as the effectiveness of the host anti-viral
immune responses (Fig. 1).
The steady-state level of HIV-1 RNA in the plasma is a
function of the rates of production and clearance — the
turnover — of the virus in circulation [1,2]. Effective anti-
viral therapy perturbs this steady state and allows an assess-
ment of the kinetic events that underlie it. Thus, virus
clearance, the magnitude of virus production, and the
longevity of virus-producing cells can all be measured.
Recent studies in which virus and infected-cell turnover are
measured in this way in persons with moderate to advanced
HIV-1 disease have shown that a very dynamic process of
virus production and clearance underlies the seemingly
static steady-state level of HIV-1 virions in the plasma [1,2]. 
Within two weeks of initiation of potent anti-viral therapy,
plasma HIV-1 RNA levels were found to fall to ~1% of
their initial values [1,2]. The slope of this initial decline in
HIV-1 RNA levels is referred to as the first-phase decay,
and reflects the clearance of virus from the circulation and
the longevity of recently infected cells. Interestingly, the
slope of the first-phase decay is remarkably constant
among different individuals (see below). The half-life of
virions in circulation is exceedingly short — about six
hours. Given such a rapid rate of virus clearance, it is esti-
mated that 109 to 1010 (or more) virions must be produced
each day to maintain the steady-state plasma HIV-1 RNA
levels typically found in persons with moderate to
advanced HIV-1 disease. When new rounds of virus repli-
cation are blocked by potent anti-viral drugs, virus produc-
tion from the vast majority of infected cells (~99%)
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Figure 1
Why is the quasi-steady state only quasi-
steady? A number of hypotheses seek to
explain the slow shift in the balance of power
between HIV-1 and the immune system. (a)
Immune surveillance could break down. This
could occur through the emergence of HIV-1
variants either that are not recognized by
cytotoxic T lymphocytes (CTLs) or that
antagonize their function. Alternatively,
otherwise competent immune surveillance by
CTLs might fail because of the loss of help
from CD4 T cells. A single host’s virus
population could evolve towards: (b) greater
cytopathicity, (c) more efficient cycles of
infection, or (d) different virus tropism, so that
CD4 cells are more efficiently infected and
destroyed. (e) Finally, more resources could
become available to the virus through
increasing target-cell generation, establishing
a vicious circle in which other infections
stimulate CD4-cell activation, providing a
resource for further growth of HIV-1, which
kills CD4 T cells and thus further impairs the
control of other infections. Unfortunately, it is
not yet known which, if any, of these
hypotheses underlie the ability of HIV-1
infection to inexorably destroy the host’s
immune defenses.
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continues for only a short period, averaging about two
days. HIV-infected cells are lost, presumably by the direct
cytopathic effects of virus infection, with the average half-
life of an infected cell being ~1.25 days, not much longer
than the length of the virus life cycle measured in tissue
culture infections. 
After the initial rapid decline in plasma RNA levels, a
slower, so-called second-phase decay of the remaining 1%
of initial plasma HIV-1 RNA levels is seen [5]. The length
of this second-phase decay varies between different indi-
viduals (lasting ~8–28 days), and is taken to be a reflection
of the decline in numbers of chronically-infected
macrophages and latently-infected T cells. Most of the
residual viremia is thought to arise from infected
macrophages that are lost with an average half-life of
about two weeks, while the remainder is produced follow-
ing activation of latently-infected T cells that decay with
an average half-life of eight days or so. Within eight weeks
of initiation of potent anti-HIV-1 therapy, plasma HIV-1
RNA levels fall below the level of the detection of even
the most sensitive plasma HIV-1 RNA assays available
(~25 copies per milliliter), indicating that de novo rounds of
HIV-1 infection are profoundly suppressed [5]. 
Fortunately, this level of suppression of HIV-1 replication
appears to be durable (> 14 months and counting!) for
patients who adhere to the complex medical regimens
demanded by current combination anti-viral therapies.
However, even this marked pharmacological interference
with HIV-1 replication has not yet been reported to eradi-
cate an established infection. Rare individuals who have
been studied after having stopped effective anti-viral
therapy following months with undetectable levels of
plasma HIV-1 RNA have all shown rapid rebounds in
HIV-1 replication. Thus, while the degree to which the
host immune response may contain HIV-1 replication
during chronic infection is not yet clear, it appears unable
to deliver a coup de grace to HIV-1 even in circumstances
where virus replication is profoundly inhibited.
When the going was good
Advocates of the importance of CTLs in the control of
HIV-1 replication in infected persons point to a variety of
evidence to support their position [6]. Firstly, CTLs have
been shown to contain and eliminate virus replication in a
number of well-studied experimental models. Secondly,
the decline in early viremia seen with resolution of primary
HIV-1 infection is temporally associated with the appear-
ance of detectable levels of anti-HIV-1 CTLs. Individuals
who, on primary infection, manifest an exaggerated, clon-
ally restricted, HIV-1-specific cytotoxic-T-cell response
have been reported to progress to disease more rapidly
than those those who mount a broader response, presum-
ably because their HIV-specific CD8 T cells are exhausted
more rapidly. Thirdly, high levels of anti-HIV-1 CTLs are
seen in established HIV-1 infections, and can often be
detected directly from the peripheral blood without in
vitro stimulation. The detection of anti-viral CTLs in the
absence of in vitro stimulation — so-called ‘fresh’ CTLs
— is claimed to be unusual in the wake of most other virus
infections. 
Lastly, progression of HIV-1 disease has been reported to
be heralded by declining levels of anti-viral CTLs, while
individuals with slowly progressive HIV-1 infection typi-
cally maintain active CTL responses. Yet even the most
vocal proponents of the importance of HIV-specific CTLs
admit that high levels of HIV-1 replication, and conse-
quent disease progression, often proceed despite
detectable CTL responses. Not only does HIV-1 persist in
the face of a vigorous immune response, but it continues
to exact incremental damage as time goes by. Thus,
although the virus and the immune response seem to
achieve a stand-off that is in quasi-steady state — that is,
population sizes change slowly relative to the rate at which
they turnover — there is nevertheless a slow shift of the
balance in favor of the virus. Why is this so? A number of
hypotheses have been proposed (Fig. 1). What they have
in common is that each suggests a process that would shift
the balance of power in favor of the virus to the detriment
of the host.
Decline and fall
Two of these hypotheses make explicit predictions about
how fast productively infected cells are cleared within
infected individuals. If progression to AIDS results from
failing immune surveillance, then one would expect indi-
viduals with more advanced disease to clear infected cells
more slowly. Conversely, if AIDS results from the virus
evolving to complete the life cycle more quickly, and thus
kill infected cells more quickly, one would expect
infected cells to disappear more quickly in individuals
with more advanced disease. When potent anti-viral drugs
became available, these ideas were tested, as described
above, by comparing the rate of clearance of cell-free virus
from treated patients who, before therapy, had different
CD4 counts [1,2] (Fig. 2). No relationship was found
between CD4 count and rate of clearance of free virus,
interpreted as indicating that people do not progress to
AIDS because their anti-viral immune response fails.
Within a year, Phillips [7] further undermined the view
that CTLs play a pivotal role in HIV-1 infection, by
pointing out that, as HIV-1 needs activated CD4 cells in
which to replicate, one might expect primary viremia to
terminate simply from the depletion of easily infectable
cells. The depletion of susceptible target cells during
primary HIV-1 infection would occur as they are lost to
the cytopathic effects of virus infection, and the level of
ongoing virus replication that could be supported there-
after would depend upon the degree to which the pool of
susceptible target cells could be replenished. Thus,
inducible anti-viral immune responses may not be neces-
sary to contain the high-level viremia of primary infec-
tion. What is more, Phillips [7] was able to cite three
studies in which infected individuals did indeed end their
primary viremia without mounting detectable specific
anti-viral immune responses.
So is the vigorous anti-HIV-1 immune response doing
nothing? This was, in fact, never the suggestion. Ho and
colleagues’ results [1,2] implied that the effect of an
immune response is not correlated with the stage of
disease, at least in its moderate to advanced stages, and
Phillips’ study [7] showed that regulation by immune
responses is not the only factor that can keep HIV-1 in
check. Nevertheless, the reputation of HIV-1-specific
CTLs was besmirched, and it seemed as if failing immune
surveillance was becoming increasingly less tenable as the
central process underlying the progression of HIV-1
disease.
Scoop
Enter Klenerman et al. [8] to defend the beleaguered
immune surveillance hypothesis. In their recent paper [8],
they suggest two scenarios in which free virus would be
cleared at similar rates in all people, even if CTL killing
were an important, but highly variable, cause of infected-
cell clearance. The first possibility requires the existence
of a small subset of productively infected cells that cannot
be killed by CTL. This leads to two different groups of
productively infected cells: target cells, subject to viral 
cytopathic effects and CTL pressure; and another group,
cleared only through viral cytopathic effects. The rate of
disappearance of free virus is a combination of the loss
rates of these two populations. In people with strong CTL
responses, the target group is small and disappears very
quickly. In people with poor CTL responses, the target
group is larger, and disappears more slowly. For the right
combinations of parameter values, these patterns can
combine to give similar rates of free virus clearance across
a broad range of CTL responsiveness.
The second possibility is that the rate of clearance of free
virus does not reflect the rate of clearance of productively
infected cells, but rather the rate at which recently infected
cells incubate their infection to become producers of virus.
To be consistent with the observed data on viral decline,
this hypothesis requires that the time from infection to pro-
duction of virus (or becoming a CTL target, whichever
comes sooner) is exponentially distributed, with a mean
duration that is long compared to the time it takes for a
virus-producing cell to be killed by viral cytopathic effects
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Predicted and observed HIV-1 clearance rates, measured by HIV-1 RNA
levels, at different CD4 counts. Predicted pattern if AIDS results from (a)
failing immune surveillance or (b) evolving cytopathic effects. (c) shows
the observed pattern [1,2]; in this study, cell-free virus was used as
surrogate for infected cells and the CD4 count was used as surrogate for
the state of disease progression, two universally accepted assumptions.
or CTL killing. This ought to be amenable to testing in a
synchronously infected in vitro culture, and efforts towards
this end have been initiated recently [9].
Unconditional surrender?
So, should the immune surveillance hypothesis be rein-
stated, or does it remain fallen? Fortunately, another
testable prediction can be extracted from the intriguing
ideas put forward by Klenerman et al. [8]. They suggest
that differences in CTL activity, as inferred from the lifes-
pans of infected cells, are hard to detect in HIV-1 infec-
tion, because they are masked by the cytopathic effects of
the virus. The lifespan of productively infected cells, and
hence the clearance rate of free virus, is bounded above by
the cytopathic effect of the virus. If the cytopathic effects
of HIV-1 infection kill target cells very quickly, any
underlying variability in CTL-induced limitation of
infected life-span would be obscured. In a case where a
virus is less cytopathic to its host cell, and kills the host
cells either slowly or not at all, there would be a much
broader spread of rates of viral clearance, and any differ-
ences in CTL activity would be more easily detected. 
The example Klenerman et al. [8] cite is chronic hepatitis
B infection, in which a broader range of free-virus clear-
ance rates is, indeed, observed. This should also apply to
HIV-1 in host cells, such as macrophages, that are less sus-
ceptible to the cytopathic effects of HIV-1. If, as observed
in tissue culture, macrophages can support productive
HIV-1 infection without being quickly killed by the virus,
then variability in the rate of clearance of such cells should
better reflect differences in host immune surveillance.
The prediction of the failing immune surveillance hypoth-
esis becomes that, for long-lived infected cells, the clear-
ance rate will be slower when the CD4 count is lower. If
Klenerman et al.’s hypothesis were correct, then failure of
CTL responses, although undetectable during the first,
fast phase of free-virus decline — the rapid clearance of
actively infected cells — would become apparent in the
second, slow phase of free-virus clearance — the clearance
of chronically infected cells, probably tissue-resident
macrophages [8]. 
In the fast moving world of HIV-1 research, this predic-
tion had been tested almost before it had been posed, and
the pattern observed is, if anything, the opposite of that
suggested by Klenerman et al. The decay of free virus has
very recently been tracked through the second, slow
phase of its post-treatment decay [5]. Rather than becom-
ing slower as disease progresses, the second-phase decay
rate is, if anything, faster in patients with lower CD4
counts. Whether this reflects higher levels of cellular acti-
vation or increased viral cytopathicity in the later stages of
the infection remain to be determined. Once again,
however, the immune surveillance hypothesis seems to be
in trouble.
Two unproven assumptions have stood at the center of
the debate about HIV-1 pathogenesis for more than ten
years: first, that CTLs play the pivotal role in regulating
the viral load of an infected individual; second, that the
failure of such immune-mediated killing of infected cells
is the precipitating event that leads to AIDS. Both of
these ideas have been rocked in the last two years. The
primacy of immune control of viral load is brought into
question by the suggestion that primary viremia can termi-
nate in the absence of detectable specific immune
responses. Similarly, the suggestion that the failure of
immune surveillance is the threshold event that individu-
als cross as they develop AIDS seems to be inconsistent
with data that show no relationship between the rate at
which infected individuals clear virus, and the degree of
damage already done to their immune system.
We are now left with two possibilities. Either we continue
to reject failing immune surveillance as the trigger of AIDS,
or we postulate that clearance of chronically infected cells is
unrelated to CTL activity. In either case, we must consider
that our in vitro assays of immune function may not
measure responses that are relevant to the in vivo circum-
stances of HIV-1 infection, and that there are major aspects
of the interaction between HIV-1 and the immune system
yet to be discovered [10]. We are brought full circle back to
the original question; why, oh why, does the immune
system allow HIV-infected cells to go on producing virus
week after week after week?
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